GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (LTS:0R1D) » Definitions » Institutional Ownership

Sangamo Therapeutics (LTS:0R1D) Institutional Ownership : 28.07% (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sangamo Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sangamo Therapeutics's institutional ownership is 28.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sangamo Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sangamo Therapeutics's Float Percentage Of Total Shares Outstanding is 99.43%.


Sangamo Therapeutics Institutional Ownership Historical Data

The historical data trend for Sangamo Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Institutional Ownership Chart

Sangamo Therapeutics Historical Data

The historical data trend for Sangamo Therapeutics can be seen below:

2023-07-31 2023-08-31 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 35.87 35.67 34.37 32.18 29.72 29.61 29.35 29.06 28.12 28.07

Sangamo Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Sangamo Therapeutics (LTS:0R1D) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Sangamo Therapeutics (LTS:0R1D) Headlines

No Headlines